Sartorius Stedim Biotech acquisition of Novasep chromatography business
On behalf of Sartorius Stedim Biotech, Nicholas Hill provided expert analysis of its proposed acquisition of the chromatography business of Novasep Process SAS. Novasep’s chromatography equipment division primarily focuses on high-pressure, multi-use applications for smaller molecules, such as oligonucleotides, peptides, and insulin. Novasep and Sartorius had collaborated on the joint development of an optimized system for a membrane-based, low-pressure chromatography that processes larger molecules more productively. Dr. Hill provided presentations to the Federal Trade Commission, which determined the transaction was unlikely to substantially lessen competition in the relevant market and approved the acquisition.
More information is available here.